A single injection of CRISPR-Cas9 gene therapy targeting the ANGPTL3 gene reduces LDL cholesterol by 50% sustainably in humans. An increasing number of genetic editing trials are currently active worldwide. Hypercholesterolemia affects several billion people, generating a significant portion of annual revenues for statins. The chronic pharmaceutical business model is wavering.
Genetic editing is scaling up. After targeting rare hereditary diseases affecting a few thousand patients, CRISPR is now tackling massive pathologies affecting hundreds of millions of people. Cholesterol is becoming the new proving ground for a medicine that repairs definitively rather than treats indefinitely.
The Essentials
- A single CRISPR injection reduces LDL cholesterol by 50% sustainably according to initial human trials
- Several billion people suffer from hypercholesterolemia worldwide
- The global statin market generates a significant portion of annual pharmaceutical revenues
- An increasing number of genetic editing trials are underway
The Injection That Replaces 30 Years of Pills
The first human trial of CRISPR gene therapy for cholesterol has just met its safety objectives. Conducted on 10 patients by Verve Therapeutics, the trial targets the ANGPTL3 gene, which regulates cholesterol production. A single intravenous injection disables this gene in liver cells, reducing LDL cholesterol levels by an average of 50% according to preliminary data published by the American Heart Association.
Treated patients maintained this reduction six months after injection, with no major side effects detected. The therapy works by directly editing the DNA of hepatocytes, the liver cells that produce 80% of blood cholesterol. Unlike statins, which temporarily inhibit an enzyme, CRISPR permanently modifies the genetic code.
This approach artificially reproduces a rare natural mutation. Approximately 1 in 10,000 people are born with a defective version of the ANGPTL3 gene and naturally have very low cholesterol levels, with no health consequences. Researchers identified this population by analyzing massive genetic databases, primarily in Pakistan and Finland where these variants are more frequent.
The technique uses lipid nanoparticles to transport CRISPR tools directly to the liver. These vectors, similar to those in mRNA vaccines against Covid-19, allow specific targeting of hepatocytes without affecting other organs. The editing occurs in vivo, directly in the patient, unlike current CRISPR therapies that modify cells in the laboratory before reinjecting them.
Billions of Potential Patients Redefining Health Economics
Hypercholesterolemia affects 39% of the global adult population according to the World Health Organization, approximately 2 billion people. Cardiovascular diseases, for which excess cholesterol is the primary risk factor, kill 17.9 million people annually. In developed countries, a significant portion of adults over 40 take statins chronically.
The global statin market generates considerable annual revenues. These medications, taken daily for decades, represent the archetype of modern pharmaceutical business: treating without curing, maintaining patient loyalty, amortizing development costs over time.
Gene therapy that treats definitively upends this equation. If a single injection costs tens of thousands of dollars—an estimate based on current gene therapies—it could remain economically advantageous compared to decades of statins. European health insurers are already calculating these trade-offs.
Public health systems could become the first adopters. The British National Health Service is already experimenting with lump-sum payments for gene therapies per cured patient, rather than per dose distributed. This logic will mechanically extend to massive chronic pathologies if sustained effectiveness is confirmed.
The Pharmaceutical Industry Faces Cannibalizing Its Revenue Streams
Verve Therapeutics, created in 2018 by Harvard cardiologists, is raising record capital. The biotech raised $200 million in 2021, then an additional $65 million in 2023. Its investors include GV (formerly Google Ventures) and funds specializing in breakthrough therapies. The company aims for market approval by 2028.
But pharmaceutical giants are adopting an ambiguous strategy. Novartis acquired The Medicines Company for $9.7 billion in 2020, simultaneously securing a competing gene therapy program for cholesterol. At the same time, the Swiss laboratory continues to invest massively in next-generation statins. This dual approach reveals the dilemma facing major groups: cannibalize their own revenue streams or allow themselves to be disrupted.
The CRISPR ecosystem is industrializing rapidly. An increasing number of genetic editing clinical trials are currently active worldwide. Targets are expanding: type 2 diabetes, obesity, high blood pressure. Each massive chronic pathology becomes a potential market for definitive genetic repair.
Regulatory authorities are accelerating their procedures. The U.S. FDA created a dedicated approval pathway for gene therapies, reducing timelines on average. The European Medicines Agency follows the same logic, considering that health urgency justifies calculated risk-taking on long-term effects.
Unequal Access to Genetic Medicine Draws a New Divide
The first approved CRISPR treatments cost between $2 and $3 million per patient. Casgevy, a gene therapy for sickle cell disease approved in 2023, charges $2.2 million per injection in the United States. These prices reflect astronomical development costs and the smallness of initial markets, but create a two-tiered medicine.
Genetic editing for cholesterol could make access achievable through volume effects. Treating millions of patients instead of thousands will allow faster amortization of investments. Vertex Pharmaceuticals, which markets Casgevy, anticipates significant price reductions through industrialization of procedures.
Emerging countries are developing their own programs. China has numerous active CRISPR trials, several targeting cardiovascular diseases. Chinese biotechs practice prices considerably lower than Western standards, creating potential competition on global markets. India and Brazil are investing massively in gene therapy production capacity.
The World Health Organization is working on equitable access mechanisms for low and middle-income countries. But the technical complexity of genetic editing limits possibilities for generic production, unlike traditional chemical drugs.
Rethinking the Insurance Model Becomes Inescapable
Health insurers are rethinking their pricing models in the face of curative therapies. Paying a significant sum upfront to avoid chronic treatment costs over several decades seems rational, but destabilizes cash flows. European mutual insurers are experimenting with staggered payments, with recovery of sums if effectiveness wanes.
French mandatory health insurance is studying funding mechanisms for these costly treatments. The principle: having the industry that saves on chronic medications contribute to financing definitive solutions. The United Kingdom is testing a similar approach.
Private companies are incorporating these therapies into their health packages. Google, Apple, and Microsoft already offer coverage of gene therapies to their employees, viewing the investment as profitable in the medium term. This corporate medicine could widen inequalities between technology sector employees and the rest of the working population.
Medical actuarial science is becoming more complex. How do you price insurance when medicine becomes predictive and preventive? Genetic tests reveal predispositions years before symptoms appear. Early genetic editing could eliminate most cardiovascular risks, but at what social and ethical cost?
Regulators Face the Challenge of Mass Genetic Editing
The extension of CRISPR to common diseases raises new regulatory questions. Genetically modifying millions of healthy people to prevent future pathologies exceeds traditional medical frameworks. The European Medicines Agency is revising its evaluation criteria, integrating socio-economic considerations with purely scientific aspects.
The question of informed consent becomes more complex. Understanding the risks of irreversible genetic editing requires expertise few patients possess. Health authorities are developing enhanced information protocols, including mandatory genetic consultations before treatment. The reflection period lengthens for non-urgent gene therapies.
Evolution of viruses and bacteria could render certain genetic modifications obsolete. Editing the immune system to resist a specific pathogenic strain presents limitations against viral mutations. Regulators now require long-term monitoring plans for all gene therapies, lengthening procedures but securing patients.
International standardization becomes crucial. Can a patient genetically edited in the United States receive care in Europe? Should national genetic registries become interoperable? The WHO coordinates standards harmonization, but national sovereignties slow integration.
Genetic medicine redefines the relationship between treatment and cure. If the anti-cholesterol injection keeps its promises, it will open the way to radical preventive medicine where genetic editing replaces chronic pharmacy. The stakes transcend technique: it is the very organization of health systems that shifts toward a definitive curative model, with its opportunities for universal access and its risks of new inequalities.
Sources
- American Heart Association - First-in-human trial of CRISPR gene editing therapy safely lowered cholesterol
- World Health Organization - Global Health Observatory